相关临床试验
34
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1895
进行中（未招募）
7
20.6%
已完成
16
47.1%
Enrolling By Invitation
4
11.8%
招募中
4
11.8%
撤回
3
8.8%
暂无批准数据
- Aston University researchers demonstrated that manuka honey's antimicrobial activity against respiratory pathogens cannot be replicated by sugar and methylglyoxal (MGO) alone. - All five UMF grades tested inhibited bacterial growth, with activity increasing alongside UMF, and methicillin-resistant Staphylococcus aureus (MRSA) proved especially vulnerable. - The findings suggest additional bioactive compounds, or interactions between compounds, drive the honey's antibacterial effects, pointing toward new approaches against antimicrobial resistance. - The team is working with Comvita Limited to identify and characterize these compounds to support development of honey-derived therapeutics.
- Aston University is leading a €1.2 million MSCA-funded MagBIO project involving 18 partner organizations to develop magnetotactic bacteria-based "magnetobots" for cancer theranostics. - The magnetobots aim to deliver anti-cancer drugs, drug-loaded liposomes, and immune-stimulating materials directly to solid tumors including pancreatic, breast, lung, and colorectal cancers. - Researchers will use external magnetic fields to guide the bacteria to tumor sites while tracking them via MRI, exploiting the bacteria's natural magnetosomes and affinity for low-oxygen environments. - The Aston team will focus on scalable, consistent biomanufacturing using bioreactors, addressing oxygen levels, nutrient supply, and sustainability to enable future clinical translation.
- Aston University and New Zealand company Comvita have filed a patent for a breakthrough Mānuka honey formulation that demonstrates superior antimicrobial activity compared to Mānuka honey alone. - Early results show the formulation is effective against highly drug-resistant bacterial species including MRSA and other pathogens causing serious hospital infections worldwide. - The development addresses the urgent global challenge of antimicrobial resistance, which the WHO projects could cause up to 10 million deaths annually by 2050. - The collaboration represents a significant milestone in translating natural antimicrobial properties into potential real-world treatments for antibiotic-resistant infections.
- Researchers from the University of Derby and Plymouth have initiated the UK's first anti-viral drug trial for long COVID, testing medication previously used only for hospitalized COVID-19 patients. - The £1.25m ERASE project involves 72 participants receiving intravenous anti-viral treatment over five days, aiming to address symptoms like fatigue, breathlessness, and brain fog affecting over 2 million UK residents. - Early participant Ryan Cawley reports significant improvement in symptoms after receiving the treatment, describing feeling "like I have been given a new pair of lungs" and experiencing an "upward trajectory to recovery."
- Aston University and Royal Orthopaedic Hospital researchers have developed an injectable gallium-doped bioglass paste that demonstrates 99% efficacy in eliminating cancer cells while promoting bone regeneration. - The innovative treatment, supported by a £110,000 grant from Orthopaedic Research UK, aims to address the 40-year plateau in bone cancer treatment advances and reduce cancer recurrence. - This breakthrough therapy could particularly benefit patients with inoperable tumors near vital organs, offering a minimally invasive alternative that can be combined with treatments like cryoablation.
